Esbriet - direct healthcare professional communication (DHPC)

Pirfenidone

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Esbriet (pirfenidone): Important safety update and new recommendations to prevent Drug-Induced Liver Injury (DILI)

Key facts

• Medicine name:
  Esbriet
• Active substance:
  Pirfenidone
• Therapeutic area (MeSH):
  Idiopathic Pulmonary Fibrosis
• Procedure number:
  EMEA/H/C/002154/II/0066/G
• Regulatory outcome:
  Variation
• DHPC type:
  Type II variation
• Human ATC codes:
  L04AX05
• Dissemination date:
  29/10/2020